ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia

This study has been completed.

Sponsored by: Fairview University Medical Center
Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00005891
  Purpose

OBJECTIVES:

I. Determine the effectiveness of moderate dose cyclophosphamide and total lymphoid radiotherapy in terms of improving the survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with Fanconi's aplastic anemia.


Condition Intervention
Fanconi's Anemia
Drug: cyclophosphamide
Procedure: Allogeneic Bone Marrow Transplantation

MedlinePlus related topics:   Anemia    Bone Marrow Transplantation   

ChemIDplus related topics:   Cyclophosphamide   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment

Further study details as provided by Office of Rare Diseases (ORD):

Study Start Date:   March 2000

Detailed Description:

PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 2 hours on day -6 through -3 and total lymphoid radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.

Patients are followed for at least 100 days.

  Eligibility
Ages Eligible for Study:   up to 54 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria
  • Diagnosis of severe aplastic anemia with the typical phenotype of Fanconi's anemia: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility
  • Family history of Fanconi's anemia
  • Histocompatible related donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00005891

Locations
United States, Minnesota
Fairview University Medical Center    
      Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators
Fairview University Medical Center

Investigators
Study Chair:     Daniel J. Weisdorf     Fairview University Medical Center    
  More Information


Study ID Numbers:   199/15099, UMN-MT-1982-10, UMN-MT-8210
First Received:   June 2, 2000
Last Updated:   June 23, 2005
ClinicalTrials.gov Identifier:   NCT00005891
Health Authority:   Unspecified

Keywords provided by Office of Rare Diseases (ORD):
Fanconi's Anemia  
aplastic anemia  
hematologic disorders  
rare disease  

Study placed in the following topic categories:
Metabolic Diseases
Fanconi's anemia
Genetic Diseases, Inborn
Hematologic Diseases
Fanconi Anemia
Rare Diseases
Anemia, Aplastic
Anemia
Cyclophosphamide
Metabolic disorder
Aplastic anemia
Bone Marrow Diseases

Additional relevant MeSH terms:
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
DNA Repair-Deficiency Disorders
Physiological Effects of Drugs
Immunosuppressive Agents
Pharmacologic Actions
Anemia, Hypoplastic, Congenital
Therapeutic Uses
Myeloablative Agonists
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Alkylating Agents

ClinicalTrials.gov processed this record on October 10, 2008




Links to all studies - primarily for crawlers